Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Zai Lab Limited | ZL-1102 | Chronic plaque psoriasis (CPP) | Phase 2 | Enrollment Initiation | Topical | Immunology: Anti-TNF |
| Zai Lab Limited | Efgartigimod | Lupus nephritis | Phase 2 | Trial Discontinued | Intravenous | Immunology |
| Zealand Pharma A/S. | Glepaglutideb (EASE-SBS 4) | Short Bowel Syndrome | Phase 3 | Subcutaneous | Gastroenterology | |
| Zealand Pharma A/S. | Glepaglutide - (EASE-SBS 2 and 3) | Short bowel syndrome (SBS) | Phase 3 | Subcutaneous | Gastroenterology | |
| Zealand Pharma A/S. | Dasiglucagon dual-hormone pump therapy | Type 1 Diabetes | Phase 3 | Subcutaneous | Endocrinology | |
| Zealand Pharma A/S. | BI 456906 | Obesity and type 2 diabetes | Phase 2 | Subcutaneous | Endocrinology | |
| Zealand Pharma A/S. | Dasiglucagon | Post bariatric surgery hypoglycemia | Phase 2a | Subcutaneous | Endocrinology | |
| Zenas BioPharma Inc. | Obexelimab - (INDIGO) | Secondary Progressive MS (SPMS) | Phase 3 | Data Released | Intravenous | Neurology |
